



BIODIEM LTD
ABN 20 096 845 993
Suite 3, Level 11,
470 Collins Street,
Melbourne, Victoria, 3000
Australia
Phone: +613 9613 4100
Web: www.biodiem.com

ASX Announcement

BioDiem's Asia Biotech Invest 2013 video presentation

Wednesday 19 June 2013. Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) has today released a BoardroomRadio (BRR) video following the Company's presentation to investors at *Asia Biotech Invest 2013*, held in Hong Kong recently.

BioDiem CEO Julie Phillips presented on the Company's business model, investment and partnership opportunities, commercial programs and technology pipeline. This includes the following points:

- Live Attenuated Influenza Virus technology outlicensed to the World Health Organisation and revenue being generated through partnerships in India and China.
- First stage of development for LAIV Vector has been completed with French-based company VIVALIS.
- SAVINE technology is aimed to address tuberculosis and also Epstein-Barr virus (EBV) related disease including nasopharyngeal cancer.
- Therapeutic hepatitis vaccine program is underway at the University of Canberra and uses BioDiem's novel approach to target Hepatitis D, B and C.
- Flavivirus research program completed at Australian National University targeting dengue fever, with potential extension into other mosquito-borne disease targets.
- BioDiem's antimicrobial program BDM-I has shown impressive activity against a broad range of disease-causing microbes and is in proof of concept animal testing in programs conducted by the National Institutes of Health, the US Military Research Institute and Queensland Institute of Medical Research.
- The four models which are currently underway for BDM-I are tuberculosis, schistosomiasis, pneumocystis and a bacterial biological warfare agent.

To view the video please go to <http://www.brrmedia.com/event/preview/43vsukek31/112540>

ENDS

About BioDiem Ltd

BioDiem (ASX: BDM) is an ASX-listed biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. The lead technology is the LAIV (Live Attenuated Influenza Virus) used for seasonal and pandemic influenza vaccines and is given intranasally. A therapeutic hepatitis vaccine project targeting hepatitis D and B is underway at the University of Canberra. BioDiem's antimicrobial, BDM-I, is in preclinical development for fungal and bacterial diseases, also schistosomiasis, tuberculosis and protozoal infections. The SAVINE (scrambled antigen) technology is in development for tuberculosis and also EBV-related disease including nasopharyngeal cancer. BioDiem's retinal product, BDM-E, in development for retinitis pigmentosa is available for outlicence.

BioDiem's research is ongoing in partnerships with internationally recognised laboratories and commercial groups. For additional information, please visit www.biodiem.com

Contact

Investors

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com

Media

Shevaun Cooper
Buchan Consulting
Phone +61 3 8866 1218 / +61 (0) 421 760 775
Email scooper@buchanwe.com.au